Wire open Last filed Lilly Pennsylvania plant breaks ground with capacity built for unapproved retatrutide RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

RoutineINDNews

Lilly Pennsylvania plant breaks ground with capacity built for unapproved retatrutide

Eli Lilly started building a 3.5 billion dollar injectables and device site in Fogelsville, due to run by 2031. Its first named product, the triple hormone peptide retatrutide, is still in Phase 3 trials.

FOGELSVILLE, PA

$3.5BLilly investment in the Fogelsville injectables and device site, due to run by 2031
  1. What's newEli Lilly broke ground on a 3.5 billion dollar injectable medicine and device site in Fogelsville, Pennsylvania, first announced in February 2026, with about 850 permanent jobs planned.
  2. Why it mattersThe plant is built to make next generation obesity drugs, led by retatrutide, a triple hormone peptide that is still in Phase 3 trials and not approved anywhere.
  3. What's nextLilly expects the site to be running by 2031. No retatrutide filing date has been announced, so approval and demand remain open questions.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. TRL · 18 Nov 2026Full SYNCHRONIZE CVOT results show survodutide was noninferior to placebo for major heart events in 5,507 high risk adults, and the lead investigator now urges flexible, individual dose escalation.
  2. TRL · 18 Nov 2026Adocia released preclinical data at ObesityWeek 2026 showing its polymer linked semaglutide, AdoXL Sema, kept its activity and lasted three to four times longer than semaglutide in pigs and rats.
  3. EXP · 18 Nov 2026Specialists told Healio that bone building drugs, including the peptides teriparatide and abaloparatide, should usually come before antiresorptives, yet most patients still start on a bisphosphonate.
  4. TRL · 17 Nov 2026Novo Nordisk presented rat, volunteer and post hoc REDEFINE 1 data at ObesityWeek 2026 suggesting that activating amylin and calcitonin receptors may limit bone loss during weight loss.
  5. REG · 17 Nov 2026From 2027 every FEHB and PSHB carrier will require documented intensive behavioral therapy before and during treatment with anti obesity medications, and most carriers are raising the GLP 1 cost share to 50%.

By the numbers

The one figure each story turns on.

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Desk fronts

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator18
  • Journal12
  • Company release29
  • Conference12
  • Our newsroom37